Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 366

1.

Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid.

Bressy C, Majhen D, Raddi N, Jdey W, Cornilleau G, Zig L, Guirouilh-Barbat J, Lopez BS, Bawa O, Opolon P, Grellier E, Benihoud K.

Oncotarget. 2017 Oct 26;8(57):97344-97360. doi: 10.18632/oncotarget.22107. eCollection 2017 Nov 14.

2.

Transcriptional landscape of a RETC634Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers.

Hadoux J, Desterke C, Féraud O, Guibert M, De Rose RF, Opolon P, Divers D, Gobbo E, Griscelli F, Schlumberger M, Bennaceur-Griscelli A, Turhan AG.

Stem Cell Res. 2018 Jan;26:8-16. doi: 10.1016/j.scr.2017.11.015. Epub 2017 Nov 23.

3.

Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma.

Leguerney I, de Rochefort L, Poirier-Quinot M, Ingels A, Violas X, Robin S, Opolon P, Dubuisson RM, Pitre-Champagnat S, Robert P, Lassau N.

Contrast Media Mol Imaging. 2017 Apr 9;2017:7498538. doi: 10.1155/2017/7498538. eCollection 2017.

4.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
5.

Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation.

Bennaceur-Griscelli A, Hadoux J, Féraud O, Opolon P, Divers D, Gobbo E, Schlumberger M, Griscelli F, Turhan AG.

Stem Cell Res. 2017 Aug;23:154-157. doi: 10.1016/j.scr.2017.07.022. Epub 2017 Jul 22.

6.

Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.

Maisonial-Besset A, Witkowski T, Navarro-Teulon I, Berthier-Vergnes O, Fois G, Zhu Y, Besse S, Bawa O, Briat A, Quintana M, Pichard A, Bonnet M, Rubinstein E, Pouget JP, Opolon P, Maigne L, Miot-Noirault E, Chezal JM, Boucheix C, Degoul F.

Oncotarget. 2017 Mar 28;8(13):22034-22047. doi: 10.18632/oncotarget.15787.

7.

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, Chen Y, Nagaraja R, Choe S, Jin L, Konteatis Z, Cianchetta G, Saunders JO, Salituro FG, Quivoron C, Opolon P, Bawa O, Saada V, Paci A, Broutin S, Bernard OA, de Botton S, Marteyn BS, Pilichowska M, Xu Y, Fang C, Jiang F, Wei W, Jin S, Silverman L, Liu W, Yang H, Dang L, Dorsch M, Penard-Lacronique V, Biller SA, Su SM.

Cancer Discov. 2017 May;7(5):478-493. doi: 10.1158/2159-8290.CD-16-1034. Epub 2017 Feb 13.

8.

Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.

Daudigeos-Dubus E, Le Dret L, Bawa O, Opolon P, Vievard A, Villa I, Bosq J, Vassal G, Geoerger B.

Int J Oncol. 2017 Jan;50(1):203-211. doi: 10.3892/ijo.2016.3792. Epub 2016 Dec 6.

PMID:
27922668
9.

CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress.

Zhang Y, Dépond M, He L, Foudi A, Kwarteng EO, Lauret E, Plo I, Desterke C, Dessen P, Fujii N, Opolon P, Herault O, Solary E, Vainchenker W, Joulin V, Louache F, Wittner M.

Sci Rep. 2016 Nov 25;6:37827. doi: 10.1038/srep37827.

10.

Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.

Telliam G, Féraud O, Griscelli F, Opolon P, Divers D, Bennaceur-Griscelli A, Turhan AG.

Stem Cell Res. 2016 Sep;17(2):235-237. doi: 10.1016/j.scr.2016.08.001. Epub 2016 Aug 4.

11.

Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation.

Hadoux J, Féraud O, Griscelli F, Opolon P, Divers D, Gobbo E, Schlumberger M, Bennaceur-Griscelli A, Turhan AG.

Stem Cell Res. 2016 Jul;17(1):154-157. doi: 10.1016/j.scr.2016.06.008. Epub 2016 Jun 27.

12.

Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Bouligand J, Richard C, Valteau-Couanet D, Orear C, Mercier L, Kessari R, Simonnard N, Munier F, Daudigeos-Dubus E, Tou B, Opolon P, Deroussent A, Paci A, Vassal G.

Pharm Res. 2016 Aug;33(8):1913-22. doi: 10.1007/s11095-016-1927-z. Epub 2016 Apr 18.

PMID:
27091031
13.

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, Bawa O, Opolon P, Vievard A, Villa I, Pagès M, Bosq J, Vassal G, Zopf D, Geoerger B.

PLoS One. 2015 Nov 23;10(11):e0142612. doi: 10.1371/journal.pone.0142612. eCollection 2015.

14.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

15.

Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model.

Ailane N, Greco C, Zhu Y, Sala-Valdés M, Billard M, Casal I, Bawa O, Opolon P, Rubinstein E, Boucheix C.

Front Physiol. 2014 Sep 19;5:364. doi: 10.3389/fphys.2014.00364. eCollection 2014.

16.

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.

Loriot Y, Mordant P, Dugue D, Geneste O, Gombos A, Opolon P, Guegan J, Perfettini JL, Pierre A, Berthier LK, Kroemer G, Soria JC, Depil S, Deutsch E.

Cell Death Dis. 2014 Sep 18;5:e1423. doi: 10.1038/cddis.2014.365.

17.

Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.

Habel N, Vilalta M, Bawa O, Opolon P, Blanco J, Fromigué O.

Oncogene. 2015 Jun 11;34(24):3207-13. doi: 10.1038/onc.2014.232. Epub 2014 Jul 28.

PMID:
25065593
18.

In vivo biodistribution and oxygenation potential of a new generation of oxygen carrier.

Le Gall T, Polard V, Rousselot M, Lotte A, Raouane M, Lehn P, Opolon P, Leize E, Deutsch E, Zal F, Montier T.

J Biotechnol. 2014 Oct 10;187:1-9. doi: 10.1016/j.jbiotec.2014.07.008. Epub 2014 Jul 15.

PMID:
25034433
19.

Establishment and characterization of new orthotopic and metastatic neuroblastoma models.

Daudigeos-Dubus E, LE Dret L, Rouffiac V, Bawa O, Leguerney I, Opolon P, Vassal G, Geoerger B.

In Vivo. 2014 Jul-Aug;28(4):425-34.

PMID:
24982206
20.

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.

Mylonas E, Janin M, Bawa O, Opolon P, David M, Quivoron C, Bernard OA, Ottolenghi C, DeBotton S, Penard-Lacronique V.

Leukemia. 2014 Jun;28(6):1343-6. doi: 10.1038/leu.2014.18. Epub 2014 Jan 14. No abstract available.

PMID:
24418992
21.

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L.

Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.

22.

Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.

Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, Secardin L, Legrand C, Galy A, Opolon P, Benyahia B, Solary E, Bernard OA, Chen L, Debili N, Raslova H, Norol F, Vainchenker W, Plo I, Di Stefano A.

PLoS One. 2013 Sep 16;8(9):e74257. doi: 10.1371/journal.pone.0074257. eCollection 2013.

23.

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.

Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L.

Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.

24.

CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.

Zhang Y, Patel S, Abdelouahab H, Wittner M, Willekens C, Shen S, Betems A, Joulin V, Opolon P, Bawa O, Pasquier F, Ito M, Fujii N, Gonin P, Solary E, Vainchenker W, Coppo P, De Botton S, Louache F.

Cell Death Dis. 2012 Oct 4;3:e396. doi: 10.1038/cddis.2012.137.

25.

A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses.

Barjon C, Niki T, Vérillaud B, Opolon P, Bedossa P, Hirashima M, Blanchin S, Wassef M, Rosen HR, Jimenez AS, Wei M, Busson P.

Infect Agent Cancer. 2012 Jul 17;7(1):16. doi: 10.1186/1750-9378-7-16.

26.

The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.

Al Nakouzi N, Bawa O, Le Pape A, Lerondel S, Gaudin C, Opolon P, Gonin P, Fizazi K, Chauchereau A.

Neoplasia. 2012 May;14(5):376-87.

27.

Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, Opolon P, Louache F, Vassal G, Laplace-Builhé C, Vielh P, Soria JC, Farace F.

Cancer Discov. 2012 May;2(5):434-49. doi: 10.1158/2159-8290.CD-11-0171. Epub 2012 Mar 30.

28.

Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.

Griscelli F, Féraud O, Oudrhiri N, Gobbo E, Casal I, Chomel JC, Biéche I, Duvillard P, Opolon P, Turhan AG, Bennaceur-Griscelli A.

Am J Pathol. 2012 May;180(5):2084-96. doi: 10.1016/j.ajpath.2012.01.011. Epub 2012 Mar 13.

PMID:
22425713
29.

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA.

Cancer Cell. 2011 Jul 12;20(1):25-38. doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.

30.

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L.

Nat Med. 2011 Jun;17(6):700-7. doi: 10.1038/nm.2366. Epub 2011 May 8.

PMID:
21552268
31.

Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions.

Klimchenko O, Di Stefano A, Geoerger B, Hamidi S, Opolon P, Robert T, Routhier M, El-Benna J, Delezoide AL, Boukour S, Lescure B, Solary E, Vainchenker W, Norol F.

Blood. 2011 Mar 17;117(11):3065-75. doi: 10.1182/blood-2010-07-295246. Epub 2010 Dec 13.

32.

HARPΔ111-136 enhances radiation-induced apoptosis of U87MG glioblastoma by induction of the proapoptotic protein CHOP.

Karaky R, Gobbo E, Opolon P, Delbé J, Courty J, Griscelli F, Perricaudet M, Martel-Renoir D.

Int J Oncol. 2011 Jan;38(1):179-88.

PMID:
21109939
33.

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.

Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N, Bénard J, Opolon P, Rozet F, Validire P, Fromont G, Fizazi K.

Exp Cell Res. 2011 Feb 1;317(3):262-75. doi: 10.1016/j.yexcr.2010.10.012. Epub 2010 Oct 23.

PMID:
20974126
34.

Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.

Leguerney I, Lassau N, Koscielny S, Rodrigues M, Massard C, Rouffiac V, Benatsou B, Thalmensi J, Bawa O, Opolon P, Peronneau P, Roche A.

Invest New Drugs. 2012 Feb;30(1):144-56. doi: 10.1007/s10637-010-9543-y. Epub 2010 Oct 6.

PMID:
20924644
35.

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.

Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, Geoerger B.

Int J Cancer. 2011 Jun 1;128(11):2748-58. doi: 10.1002/ijc.25611. Epub 2010 Oct 8.

36.

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, Vrignaud P, Vassal G.

Eur J Cancer. 2010 Dec;46(18):3251-62. doi: 10.1016/j.ejca.2010.06.005. Epub 2010 Jun 28.

PMID:
20591650
37.

Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity.

Monceau V, Pasinetti N, Schupp C, Pouzoulet F, Opolon P, Vozenin MC.

Curr Drug Targets. 2010 Nov;11(11):1395-404.

PMID:
20583978
38.

The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation.

Li H, Shi X, Liu J, Hu C, Zhang X, Liu H, Jin J, Opolon P, Vannier JP, Perricaudet M, Janin A, Soria C, Lu H.

Cancer Gene Ther. 2010 Oct;17(10):700-7. doi: 10.1038/cgt.2010.26. Epub 2010 Jun 18.

PMID:
20559333
39.

The anti-angiogenic activity of IL-12 is increased in iNOS-/- mice and involves NK cells.

Bielawska-Pohl A, Blesson S, Benlalam H, Trenado A, Opolon P, Bawa O, Rouffiac V, Dus D, Kieda C, Chouaib S.

J Mol Med (Berl). 2010 Aug;88(8):775-84. doi: 10.1007/s00109-010-0620-7. Epub 2010 Apr 11.

PMID:
20383693
40.

The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis.

Guihard S, Clay D, Cocault L, Saulnier N, Opolon P, Souyri M, Pagès G, Pouysségur J, Porteu F, Gaudry M.

Blood. 2010 May 6;115(18):3686-94. doi: 10.1182/blood-2009-09-242487. Epub 2010 Mar 11.

41.

Antitumorigenic effects of a mutant of the heparin affin regulatory peptide on the U87 MG glioblastoma cell line.

Dos Santos C, Karaky R, Renoir D, Hamma-Kourbali Y, Albanese P, Gobbo E, Griscelli F, Opolon P, Dalle S, Perricaudet M, Courty J, Delbé J.

Int J Cancer. 2010 Sep 1;127(5):1038-51. doi: 10.1002/ijc.25110.

42.

Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts.

Bouclier C, Marsaud V, Bawa O, Nicolas V, Moine L, Opolon P, Renoir JM.

Breast Cancer Res Treat. 2010 Jul;122(1):145-58. doi: 10.1007/s10549-009-0558-z. Epub 2009 Sep 22.

PMID:
19771505
43.

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.

Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, Kroemer G, Deutsch E.

Cell Cycle. 2009 Oct 1;8(19):3172-81. Epub 2009 Oct 4.

PMID:
19755861
44.

Syncytin-A knockout mice demonstrate the critical role in placentation of a fusogenic, endogenous retrovirus-derived, envelope gene.

Dupressoir A, Vernochet C, Bawa O, Harper F, Pierron G, Opolon P, Heidmann T.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12127-32. doi: 10.1073/pnas.0902925106. Epub 2009 Jun 29.

45.

Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.

Mangoni M, Yue X, Morin C, Violot D, Frascogna V, Tao Y, Opolon P, Castaing M, Auperin A, Biti G, Barritault D, Vozenin-Brotons MC, Deutsch E, Bourhis J.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1242-50. doi: 10.1016/j.ijrobp.2009.03.006.

PMID:
19545790
46.

Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G; Innovative Therapies for Children with Cancer European Consortium.

Eur J Cancer. 2009 Sep;45(13):2342-51. doi: 10.1016/j.ejca.2009.03.007. Epub 2009 Apr 9.

PMID:
19362466
47.

Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells.

Amine A, Rivera S, Opolon P, Dekkal M, Biard DS, Bouamar H, Louache F, McKay MJ, Bourhis J, Deutsch E, Vozenin-Brotons MC.

PLoS One. 2009;4(3):e5018. doi: 10.1371/journal.pone.0005018. Epub 2009 Mar 26.

48.

Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.

Zanta-Boussif MA, Charrier S, Brice-Ouzet A, Martin S, Opolon P, Thrasher AJ, Hope TJ, Galy A.

Gene Ther. 2009 May;16(5):605-19. doi: 10.1038/gt.2009.3. Epub 2009 Mar 5.

PMID:
19262615
49.

Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.

Maggiorella L, Aubel C, Haton C, Milliat F, Connault E, Opolon P, Deutsch E, Bourhis J.

Cell Prolif. 2009 Feb;42(1):38-48. doi: 10.1111/j.1365-2184.2008.00570.x.

PMID:
19143762
50.

Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells.

Mabrouk I, Buart S, Hasmim M, Michiels C, Connault E, Opolon P, Chiocchia G, Lévi-Strauss M, Chouaib S, Karray S.

Immunity. 2008 Dec 19;29(6):922-33. doi: 10.1016/j.immuni.2008.10.007. Epub 2008 Nov 13.

Supplemental Content

Loading ...
Support Center